Table 2. Epidemiological, clinical and neurological profile of patients with nonbacterial neurological disorders according to etiological diagnosis.
| Characteristics | Other etiology (n = 48) | Chikungunya (n = 55) | Dengue (n = 18) | Dengue & chikungunya (n = 16) | Zika (n = 4) | p-value |
|---|---|---|---|---|---|---|
| Ageb | 43 (17; 63) | 63 (42; 74) | 19 (3; 43) | 28 (17; 50) | 56 (49;61) | 0.002a |
| Sex: Female | 24 (50.0%) | 24 (43.6%) | 8 (44.4%) | 11 (68.7%) | 3 (75.0%) | 0.360 |
| Originating from | ||||||
| Recife | 9 (18.8%) | 13 (23.6%) | 3 (16.7%) | 9 (56.2%) | 0 (0%) | 0.036a |
| Metropolitan Region of Recife | 23 (47.9%) | 14 (25.5%) | 7 (38.9%) | 4 (25.0%) | 2 (50.0%) | |
| Interior | 16 (33.3%) | 28 (50.9%) | 8 (44.4%) | 3 (18.7%) | 2 (50.0%) | |
| Time spent in hospital (days)b | 13 (7; 24) | 15 (7; 23) | 11 (4; 23) | 11 (7; 34) | 8 (1; 16) | 0.828 |
| Symptoms | ||||||
| Fever | 40 (85.1%) | 51 (92.7%) | 18 (100%) | 12 (75.0%) | 4 (100%) | 0.123c |
| Myalgia | 27 (56.2%) | 32 (58.2%) | 3(72.2%) | 7 (43.7%) | 2 (50.0%) | 0.563 |
| headache | 26 (54.2%) | 25 (45.5%) | 6 (33.3%) | 9 (56.2%) | 1 (25.0%) | 0.448 |
| Strong Arthralgia | 15 (31.2%) | 32 (58.2%) | 4 (22.2%) | 9 (56.2%) | 3 (75.0%) | 0.053c |
| Comorbidities | ||||||
| SAH | 16 (33.3%) | 22 (40.0%) | 4 (22.2%) | 5 (31.2%) | 2 (50.0%) | 0.663c |
| Diabetes | 6 (12.5%) | 12 (21.8%) | 2 (11.1%) | 2 (2.7%) | 2 (50.0%) | 0.275c |
| Neurological Manifestations | ||||||
| Loss of strength in lower limbs | 30 (62.5%) | 29 (52.7%) | 9 (50.0%) | 12 (75.0%) | 2 (50.0%) | 0.477 |
| Changes in ambulation | 25 (52.1%) | 20 (36.4%) | 7 (38.9%) | 7 (43.7%) | 1 (25.0%) | 0.516 |
| Reduced level of conscientiousness | 13 (27.1%) | 31 (56.4%) | 9 (50.0%) | 7 (43.5%) | 2 (50.0%) | 0.040ac |
| Disorientation | 7 (14.6%) | 27 (49.1%) | 3 (16.7%) | 5 (31.2%) | 0 (0%) | 0.001c |
| Change in sensitivity | 6 (12.5%) | 6 (10.9%) | 3 (16.7%) | 3 (18.7%) | 3 (75.0%) | 0.042ac |
| Duration of neurologic symptoms (days)b | 19 (7; 34) | 14 (6; 28) | 13 (6; 40) | 13 (9; 41) | 17 (3; 33) | 0.765 |
| Initial time of symptoms and neurological disorders (days)b | 7 (3; 32) | 6 (3; 16) | 10 (3; 17) | 4.5 (2.5; 6) | 37 (3; 105) | 0.446 |
| Neurological disorder | ||||||
| Myelitis | 10 (20.8%) | 3 (5.4%) | 3 (16.7%) | 2 (12.5%) | 1 (25.0%) | 0.039c |
| GBS | 13 (27.1%) | 16 (29.1%) | 3 (16.7%) | 4 (25.0%) | 1 (25.0%) | |
| Encephalitis | 0 (0%) | 12 (21.8%) | 4 (22.2%) | 2 (12.5%) | 0 (0%) | |
| Meningoencephalitis | 1 (2.1%) | 6 (10.9%) | 0 (0%) | 3 (18.7%) | 0 (0%) | |
| Others | 24 (50.0%) | 18 (32.7%) | 8 (44.4%) | 5 (31.2%) | 2 (50.0%) |
aSignificant statistical difference; bMedian (P25; P75); cFischer Exact Test